10 Best Low Volatility Stocks to Buy Now

4. Eli Lilly and Company (NYSE:LLY)

5-Year Monthly Beta: 0.5

No. of Hedge Fund Holders: 115

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company focused on discovering, developing, and marketing human pharmaceuticals. The company offers a wide range of treatments across several therapeutic areas, with a portfolio that includes various insulin formulations under the Humalog and Humulin brands, as well as newer medications like Jardiance, Mounjaro, Trulicity, and Zepbound for obesity and type 2 diabetes.

While pharmaceuticals have often been exempted from direct tariffs, the broader implications of a trade war and potential future tariffs specifically targeting the sector are expected to impact LLY. Eli Lilly and Company (NYSE:LLY) actively collaborates with other pharmaceutical and biotechnology companies, including Incyte, Boehringer Ingelheim, Roche, and others, to advance its research and development efforts across its diverse therapeutic pipeline. The company markets its products in the United States, Europe, China, Japan, and other international markets. To offset the impact of new tariffs on margins, the pharmaceutical giant continues to deliver high-quality medicine to patients globally by setting up local manufacturing to offset fears of supply chain constraints.

Eli Lilly and Company (NYSE:LLY) has made eight acquisitions and signed three agreements over the past 27 months, as per the company’s press releases. These begin from DICE Therapeutics in June of 2023 to the most recent Scorpion Therapeutics in January 2025. These strategic acquisitions are key to achieving continued growth into new markets.

Eli Lilly and Company (NYSE:LLY) stock price surged recently, following the successful completion of a Phase 3 trial for orforglipron, its once-daily oral GLP-1 medication. The drug effectively met both the primary and key secondary endpoints in patients with type 2 diabetes. This positive outcome has significantly increased investor optimism regarding Lilly’s competitive position within the rapidly expanding obesity drug market.